BTIG Reiterates Buy Rating on Progenics Pharmaceuticals (PGNX)
BTIG analyst Timothy Chiang reiterated a Buy rating and $14.00 price target on Progenics Pharmaceuticals (NASDAQ: PGNX), citing Multiple Upcoming ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)